Cargando…

Patient values and preferences when choosing anticoagulants

BACKGROUND: New oral anticoagulants have similar efficacy and lower bleeding rates compared with warfarin. However, in case of bleeding there is no specific antidote to reverse their effects. We evaluated the preferences and values of anticoagulants of patients at risk of atrial fibrillation and tho...

Descripción completa

Detalles Bibliográficos
Autores principales: Palacio, Ana M, Kirolos, Irene, Tamariz, Leonardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309777/
https://www.ncbi.nlm.nih.gov/pubmed/25653506
http://dx.doi.org/10.2147/PPA.S64295
_version_ 1782354746133184512
author Palacio, Ana M
Kirolos, Irene
Tamariz, Leonardo
author_facet Palacio, Ana M
Kirolos, Irene
Tamariz, Leonardo
author_sort Palacio, Ana M
collection PubMed
description BACKGROUND: New oral anticoagulants have similar efficacy and lower bleeding rates compared with warfarin. However, in case of bleeding there is no specific antidote to reverse their effects. We evaluated the preferences and values of anticoagulants of patients at risk of atrial fibrillation and those who have already made a decision regarding anticoagulation. METHODS: We conducted a cross-sectional study of Veterans in the primary care clinics and the international normalized ratio (INR) laboratory. We developed an instrument with patient and physician input to measure patient values and preferences. The survey contained a hypothetical scenario of the risk of atrial fibrillation and the attributes of each anticoagulant. After the scenario, we asked participants to choose the option that best fits their preferences. The options were: 1) has better efficacy at reducing risk of stroke; 2) has been in the market for a long period of time; 3) has an antidote to reverse the rare case of bleeding; 4) has better quality of life profile with no required frequent laboratory tests; or 5) I want to follow physician recommendations. We stratified our results by those patients who are currently exposed to anticoagulants and those who are not exposed but are at risk of atrial fibrillation. RESULTS: We approached 173 Veterans and completed 137 surveys (79% response rate). Ninety subjects were not exposed to anticoagulants, 46 reported being on warfarin, and one reported being on dabigatran at the time of the survey. Ninety-eight percent of subjects stated they would like to participate in the decision-making process of selecting an anticoagulant. Thirty-six percent of those exposed and 37% of those unexposed to anticoagulants reported that they would select a medication that has an antidote even if the risk of bleeding was very small. Twenty-three percent of the unexposed and 22% of the exposed groups reported that they would prefer the medication that gives the best quality of life. CONCLUSION: Our study found that patients who may be exposed to an anticoagulation decision prefer to actively participate in the decision-making process, and have individual values for making a decision that cannot be predicted or assumed by anyone in the health care system.
format Online
Article
Text
id pubmed-4309777
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-43097772015-02-04 Patient values and preferences when choosing anticoagulants Palacio, Ana M Kirolos, Irene Tamariz, Leonardo Patient Prefer Adherence Original Research BACKGROUND: New oral anticoagulants have similar efficacy and lower bleeding rates compared with warfarin. However, in case of bleeding there is no specific antidote to reverse their effects. We evaluated the preferences and values of anticoagulants of patients at risk of atrial fibrillation and those who have already made a decision regarding anticoagulation. METHODS: We conducted a cross-sectional study of Veterans in the primary care clinics and the international normalized ratio (INR) laboratory. We developed an instrument with patient and physician input to measure patient values and preferences. The survey contained a hypothetical scenario of the risk of atrial fibrillation and the attributes of each anticoagulant. After the scenario, we asked participants to choose the option that best fits their preferences. The options were: 1) has better efficacy at reducing risk of stroke; 2) has been in the market for a long period of time; 3) has an antidote to reverse the rare case of bleeding; 4) has better quality of life profile with no required frequent laboratory tests; or 5) I want to follow physician recommendations. We stratified our results by those patients who are currently exposed to anticoagulants and those who are not exposed but are at risk of atrial fibrillation. RESULTS: We approached 173 Veterans and completed 137 surveys (79% response rate). Ninety subjects were not exposed to anticoagulants, 46 reported being on warfarin, and one reported being on dabigatran at the time of the survey. Ninety-eight percent of subjects stated they would like to participate in the decision-making process of selecting an anticoagulant. Thirty-six percent of those exposed and 37% of those unexposed to anticoagulants reported that they would select a medication that has an antidote even if the risk of bleeding was very small. Twenty-three percent of the unexposed and 22% of the exposed groups reported that they would prefer the medication that gives the best quality of life. CONCLUSION: Our study found that patients who may be exposed to an anticoagulation decision prefer to actively participate in the decision-making process, and have individual values for making a decision that cannot be predicted or assumed by anyone in the health care system. Dove Medical Press 2015-01-22 /pmc/articles/PMC4309777/ /pubmed/25653506 http://dx.doi.org/10.2147/PPA.S64295 Text en © 2015 Palacio et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Palacio, Ana M
Kirolos, Irene
Tamariz, Leonardo
Patient values and preferences when choosing anticoagulants
title Patient values and preferences when choosing anticoagulants
title_full Patient values and preferences when choosing anticoagulants
title_fullStr Patient values and preferences when choosing anticoagulants
title_full_unstemmed Patient values and preferences when choosing anticoagulants
title_short Patient values and preferences when choosing anticoagulants
title_sort patient values and preferences when choosing anticoagulants
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309777/
https://www.ncbi.nlm.nih.gov/pubmed/25653506
http://dx.doi.org/10.2147/PPA.S64295
work_keys_str_mv AT palacioanam patientvaluesandpreferenceswhenchoosinganticoagulants
AT kirolosirene patientvaluesandpreferenceswhenchoosinganticoagulants
AT tamarizleonardo patientvaluesandpreferenceswhenchoosinganticoagulants